Samsung Bioepis Sees Success With Soliris Biosimilar

SB12 Eculizumab Candidate Demonstrates Equivalence In Phase III Trial

 
• By Dave Wallace

Samsung Bioepis has reported positive Phase III data for its SB12 proposed eculizumab biosimilar to Soliris, with the product showing equivalence in efficacy, safety, PK, PD and immunogenicity.

Pen tick check list boxes
SB12 showed equivalence in efficacy, safety, PK, PD and immunogenicity • Source: Shutterstock

More from Biosimilars

More from Products